Case Series| Volume 20, ISSUE 6, P586-590, December 2022

Download started.


Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer

      Clinical Practice Points

      • 5-FU infusion has activity in far advanced prostate cancer.
      • 5-FU at 200 mg/M2 per day by continuous infusion is well tolerated.
      • Options for advanced prostate cancer are limited.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ghosh Roy S.
        Castrate-Resistant Prostate Cancer.
        in: Schwab M Encyclopedia of Cancer. Springer Berlin Heidelberg, Berlin, Heidelberg2016: 1-4
        • Liang JT
        • Huang KC
        • Cheng YM
        • et al.
        P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
        Int J cancer. 2002; 97: 451-457
        • Kirby M
        • Hirst C
        • Crawford ED.
        Characterising the castration-resistant prostate cancer population: a systematic review.
        Int J Clin Pract. 2011; 65: 1180-1192
        • Albala DM.
        Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.
        Rev Urol. 2017; 19: 200-202
        • Wen L
        • Yao J
        • Valderrama A.
        Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases.
        J Manag Care Spec Pharm. 2019; 25: S1-S11
        • Huang X
        • Chau CH
        • Figg WD.
        Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
        J Hematol Oncol. 2012; 5: 35
        • Punnen S
        • Cooperberg MR
        • D'Amico AV
        • et al.
        Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.
        Euro Urol. 2013; 64: 905-915
        • Jordan VC
        A retrospective: on clinical studies with 5-Fluorouracil.
        Cancer Res. 2016; 76: 767-768
        • Light DW
        • Lexchin JR.
        Pharmaceutical research and development: what do we get for all that money?.
        Bmj. 2012; 345: e4348
        • Swanson GP
        • Faulkner J
        • Smalley SR
        • et al.
        Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest oncology group study 9024.
        J urol. 2006; 176 (discussion 553): 548-553
        • Longley DB
        • Harkin DP
        • Johnston PG.
        5-fluorouracil: mechanisms of action and clinical strategies.
        Nat rev Cancer. 2003; 3: 330-338
        • Ghoshal K
        • ST Jacob
        An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug.
        Biochem Pharmacol. 1997; 53: 1569-1575
        • Lamberti M
        • Porto S
        • Marra M
        • et al.
        5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress.
        J Exp Clin Cancer Res. 2012; 31: 60
        • Macdonald JS.
        Toxicity of 5-fluorouracil.
        Oncology (Williston Park). 1999; 13: 33-34
        • Kuzel TM
        • Tallman MS
        • Shevrin D
        • et al.
        A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
        Cancer. 1993; 72: 1965-1968
        • Atkins JN
        • Muss HB
        • Case D
        • et al.
        High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
        Am J Clin Oncol. 1991; 14: 526-529
        • Spicer J
        • Plunkett T
        • Somaiah N
        • et al.
        Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer.
        Prostate cancer prostatic dis. 2005; 8: 364-368
        • Morant R
        • Bernhard J
        • Dietrich D
        • et al.
        Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
        Br J cancer. 2004; 90: 1312-1317
        • Hansen R
        • Moynihan T
        • Beatty P
        • et al.
        Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer.
        Urology. 1991; 37: 358-361
        • Manogue C
        • Cotogno P
        • Moses MM
        • et al.
        Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: an update.
        JClinl Oncol. 2019; 37 (-319): 319
        • Manogue C
        • Ledet E
        • Guddati AK
        • Lewis B
        • Sartor O.
        Extreme prostate-specific antigen response to infusional 5-Flourouracil in castrate-resistant prostate cancer.
        Oncologist. 2018; 23: 383-385